[Early risk factors for secondary hyperparathyroidism in hemodialysis patients]. 2005

Vaida Petrauskiene, and Inga Arūne Bumblyte, and Vytautas Kuzminskis, and Egle Sepetauskiene
Clinic of Nephrology, Kaunas University of Medicine, Eiveniu 2, 50009 Kaunas, Lithuania. petrauskai127@hotmail.com

The aim of the study was to identify risk factors for secondary hyperparathyroidism at the start and during the first year of hemodialysis. Retrospective analysis of medical records of all patients with end-stage renal disease, dialyzed at the hemodialysis center of Kaunas University of Medicine Hospital on December 2004, was performed. Biochemical data at the start, during the first year and at the end of follow-up (December 2004) were analyzed. At the start of hemodialysis elevated level of parathyroid hormone (PTH) was observed in 46 of 69 patients (67.6%), at the end of the first year in 27 of 69 patients (39.1%). In 22 of 46 patients (47.8%), who started hemodialysis with elevated PTH levels, the level of PTH decreased to <22 pmol/l after 1 year. In comparison with patients who maintained elevated PTH levels, they showed lower levels of PTH at the start of hemodialysis. Levels of serum calcium and phosphate at the start of hemodialysis did not differ between groups. At the end of the first year patients in whom levels of PTH decreased had higher serum calcium concentration as compared with those who maintained levels of PTH > or =22 pmol/l. A multivariate analysis revealed that levels of PTH and alkaline phosphatase after one year of hemodialysis were associated with increased risk for secondary hyperparathyroidism on the follow up. CONCLUSIONS Control of calcium-phosphate metabolism in the pre-dialysis period is not sufficient. Symptoms of secondary hyperparathyroidism were diagnosed in more than a half of patients starting hemodialysis. Levels of PTH and alkaline phosphatase at the end of the first year are early risk factors for secondary hyperparathyroidism on the follow-up.

UI MeSH Term Description Entries
D006962 Hyperparathyroidism, Secondary Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY. Secondary Hyperparathyroidism,Hyperparathyroidisms, Secondary,Secondary Hyperparathyroidisms
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Vaida Petrauskiene, and Inga Arūne Bumblyte, and Vytautas Kuzminskis, and Egle Sepetauskiene
August 1986, World journal of surgery,
Vaida Petrauskiene, and Inga Arūne Bumblyte, and Vytautas Kuzminskis, and Egle Sepetauskiene
April 2004, The New England journal of medicine,
Vaida Petrauskiene, and Inga Arūne Bumblyte, and Vytautas Kuzminskis, and Egle Sepetauskiene
November 2009, Transplantation proceedings,
Vaida Petrauskiene, and Inga Arūne Bumblyte, and Vytautas Kuzminskis, and Egle Sepetauskiene
January 2010, Medicinski pregled,
Vaida Petrauskiene, and Inga Arūne Bumblyte, and Vytautas Kuzminskis, and Egle Sepetauskiene
December 2011, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy,
Vaida Petrauskiene, and Inga Arūne Bumblyte, and Vytautas Kuzminskis, and Egle Sepetauskiene
January 2005, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry,
Vaida Petrauskiene, and Inga Arūne Bumblyte, and Vytautas Kuzminskis, and Egle Sepetauskiene
November 1982, The Tokai journal of experimental and clinical medicine,
Vaida Petrauskiene, and Inga Arūne Bumblyte, and Vytautas Kuzminskis, and Egle Sepetauskiene
December 2017, Polish archives of internal medicine,
Vaida Petrauskiene, and Inga Arūne Bumblyte, and Vytautas Kuzminskis, and Egle Sepetauskiene
January 2022, PloS one,
Vaida Petrauskiene, and Inga Arūne Bumblyte, and Vytautas Kuzminskis, and Egle Sepetauskiene
July 2017, BMC nephrology,
Copied contents to your clipboard!